Skip to navigation Skip to content

Clinical Trial: Remibrutinib vs. Teriflunomide in Relapsing-Remitting MS

Share

Details
Type of MS: RRMS
Number of Subjects: 800
Medication: Remibrutinib vs. Teriflunomide (Aubagio)
Location: Florida
Institutions: Vero Beach Neurology and Reseach Institiute
1040  37th Place  #201   
Vero Beach FL   32960 Contact Information
Clellia Bergamino, ext. 228
772-492-7051
cbergamino@geodysseyrsch.com

Funding:


Novartis Pharmaceuticals

Description

Remibrutinib inhibits an enzyme called “Bruton’s tyrosine kinase,” reducing the activation of B cells, which are immune cells that play a role in the response that affects the brain and spinal cord in MS.  This study is comparing the safety and effectiveness of oral Remibrutinib to oral Aubagio® (teriflunomide, Genzyme Sanofi). Participants will undergo blood draws, MRI scans of the brain, and study visits. A stipend will be provided for time and travel. 
 

Share

© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.